Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons | The Manila Times

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 7 February 2025 - This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler
2	Reason for the notification
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, Get the latest news delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy. type of instrument,	Shares Advertisement
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c) Advertisement Advertisement	Price(s) and volume(s) Advertisement Advertisement
			Price(s)	Volume(s)
			DKK 620.26	40,000 shares


d)	Aggregated information Aggregated volume Price	40,000 shares DKK 24,810,329
e)	Date of the transaction	2025-02-06
f)	Place of the transaction	Nasdaq Copenhagen

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

[email protected]

Liz Skrbkova (US)

+1 609 917 0632

[email protected]

Investors:

Jacob Martin Wiborg Rode

+45 3075 5956

[email protected]